BioCryst to Raise Approximately $23.9 Million Through Sale of Common Stock

BioCryst Pharmaceuticals, Inc. announced that it has priced a registered direct offering for the sale of 4,350,000 shares of its common stock at a price of $5.50 per share to institutional investors. Leerink, Swann & Company served as placement agent for the transaction. The company expects this transaction to close on Friday, Feb. 18, 2005.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-17-2005/0003027380&EDATE=)